• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets), a new low-dose birth control pill, has been approved for marketing. New Alesse represents the lowest dose combination of levonorgestrel and ethinyl estradiol marketed in the United States. Alesse contains 100 mcg of the progestin levonorgestrel, the most widely prescribed contraceptive progestin, and 20 mcg of ethinyl estradiol, the estrogen most frequently used in oral contraceptives. More than 40 percent of oral contraceptive prescriptions worldwide contain levonorgestrel and ethinyl estradiol. Alesse, packaged in the Mini-Pack, is available in 21- and 28-day regimens. The Mini-Pack, developed by Wyeth-Ayerst, represents the smallest oral contraceptive packaging available. It has several convenient features to help women remember to take their birth control pill daily and in the prescribed sequence.

    Alesse, like other oral contraceptive, has proven to be more than 99 percent effective when taken as directed. In addition, birth control pills may provide protection from ovarian and endometrial cancer and pelvic inflammatory disease. They also may make a woman’s period less painful by reducing cramps and increase menstrual cycle regularity. Women who use Alesse or other oral contraceptives may experience iron-deficiency anemia and ectopic pregnancy less frequently.

    Side Effects

    Common side effects associated with oral contraceptives include nausea, headache and breast tenderness. Serious side effects occur infrequently, especially if a woman is in good health and does not smoke. These may include blood clots, heart disease, stroke, liver tumors and gallbladder disease. Several studies have found no overall increase in the risk of developing breast cancer in women taking oral contraceptives. Some women should not use oral contraceptives, including those who have had blood clots, certain cancers, or a history of heart attack or stroke, as well as those who are or may be pregnant.

    Additional Information

    Cigarette smoking increases the risk of serious cardiovascular side effects. This risk increases with age and is most pronounced in women older than age 35. Women on oral contraceptives should not smoke. In addition, oral contraceptives do not protect a woman against HIV infection or other sexually transmitted diseases.

    Approval Date: 1997-04-01
    Company Name: Wyeth
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing